In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
about
Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent.The application of in vitro methods to safety pharmacology.Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correctionThe utility of the small rodent electrocardiogram in toxicology.Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs.Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties.Chemically Homogenous Compounds with Antagonistic Properties at All α1-Adrenoceptor Subtypes but not β1-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in RatsEffects of three fluoroquinolones on QT analysis after standard treatment courses.Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
P2860
Q33396650-7F4D2244-EAE1-41C5-9C75-BF6466258361Q33560293-11907114-423A-40E9-9EA5-683E89D47996Q34775509-A3591566-4A4F-4D37-A612-C6BCB064018FQ36176544-DC48689B-2A48-417C-81F0-71C8BADD1EE8Q36753833-4ED4C135-DE32-47AA-9A48-3B2FC9113477Q37833375-F4ABE5D0-04A2-4400-83CA-EFC0A1801163Q39924256-74C25143-7FDC-4789-AF51-B25AD5ADB032Q41644207-49EDBCED-8B74-423B-BFC5-C9E6866D39AFQ42058859-25B8C344-A1B9-4F60-AA41-51FF0ABF86E5Q42680174-56A2A20B-3A5D-48E8-AE3C-43A9D7A0E0A5Q51769606-E8A8DB73-A8DB-4E51-8D65-5DF9401D462D
P2860
In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vivo measurement of QT prol ...... logy of a new chemical entity.
@ast
In vivo measurement of QT prol ...... logy of a new chemical entity.
@en
In vivo measurement of QT prol ...... logy of a new chemical entity.
@nl
type
label
In vivo measurement of QT prol ...... logy of a new chemical entity.
@ast
In vivo measurement of QT prol ...... logy of a new chemical entity.
@en
In vivo measurement of QT prol ...... logy of a new chemical entity.
@nl
prefLabel
In vivo measurement of QT prol ...... logy of a new chemical entity.
@ast
In vivo measurement of QT prol ...... logy of a new chemical entity.
@en
In vivo measurement of QT prol ...... logy of a new chemical entity.
@nl
P2093
P2860
P1476
In vivo measurement of QT prol ...... logy of a new chemical entity.
@en
P2093
An Hermans
André Van de Water
Fred De Clerck
Hua Rong Lu
Jan D'Aubioul
Karel Van Ammel
Koen van Rossem
P2860
P304
P356
10.1046/J.1472-8206.2002.00081.X
P577
2002-04-01T00:00:00Z